Ireland - English - HPRA (Health Products Regulatory Authority)

andres pintaluba s.a. - colistin (as sulfate) - premix for med.feedstuffs - 1,200,000 international unit - colistin - porcine - antibiotics

Ireland - English - HPRA (Health Products Regulatory Authority)

andres pintaluba s.a. - colistin - premix for medicated feeding stuff - 1,200,000 international unit(s)/gram - colistin - pigs - antibiotics

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon nasal solution is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. calcitonin salmon nasal solution should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4)]. - calcitonin salmon nasal solution has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1)]. risk summary calcitonin salmon nasal solution is not i

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc.(dba leucadia pharmaceuticals) - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. calcitonin salmon injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furose

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. calcitonin salmon injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furose

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 2200 [iu] in 1 ml - fortical® calcitonin-salmon (rdna origin) nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. use of fortical® calcitonin-salmon (rdna origin) nasal spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin d (400 international units per day) intake to retard the progressive loss of bone mass. the evidence of efficacy for calcitonin-salmon is based on increases in spinal bone mineral density (bmd) observed in clinical trials. two randomized, placebo-controlled trials were conducted in 325 postmenopausal women (227 treated with calcitonin-salmon nasal spray and 98 treated with placebo) with spinal, forearm or femoral bmd at least one standard deviation below the normal value for healthy premenopausal women. these studies conducted over two years demonstrated that 200 international units daily of calcitonin-salmon nasal spray

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 2200 [iu] in 1 ml - fortical nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. fortical nasal spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4) ]. - calcitonin-salmon nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1) ]. pregnancy category c: risk summary there are no adequate and well-controlled

United States - English - NLM (National Library of Medicine)

mylan institutional llc - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 200 [iu] in 1 ml - miacalcin injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or

Canada - English - Health Canada

pro doc limitee - calcitonin (salmon synthetic) - solution - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios richet, s.a. - colistina ( metansulfonato de sodio) - colistina ( metansulfonato de sodio)....100.0 mg. / agua destilada para inyectables....2.0 ml.